BioCryst Pharmaceuticals | BCRX - Actif À Court Terme





Actif À Court Terme Changement Date
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
BioCryst Pharmaceuticals USD 484.68M 111.06M 2026-06
Chugai Pharma JPY 1.7T 164.75B 2026-06
Daiichi Sankyo JPY 2.23T 91.92B 2026-06
DBV Technologies USD 201.9M 44.8M 2026-06
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 12.53B 6.11B 2026-06
GlaxoSmithKline GBP 17.56B 202M 2026-06
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Incyte USD 6.03B 542.31M 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
Karyopharm Therapeutics USD 126.33M 23.19M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Novavax USD 771.1M 79.72M 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Roche Holding CHF 35.44B 3.29B 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Ultragenyx Pharmaceutical USD 606M 51M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06